Revolution Medicines (RVMD) Tax Provisions (2020 - 2024)
Revolution Medicines (RVMD) posted quarterly Tax Provisions of -$800000.0 for Q4 2024, down 119.09% year-over-year from $4.2 million in Q1 2024, and down 119.09% quarter-over-quarter from $4.2 million in Q4 2023.
Revolution Medicines (RVMD) Tax Provisions (2020 - 2024) Analysis & Trends
Revolution Medicines' Tax Provisions history runs 4 years deep, the most recent figure standing at -$800000.0 for Q4 2024.
- In Q4 2024, Tax Provisions fell 119.09% year-over-year to -$800000.0; the TTM figure through Dec 2024 stood at -$800000.0 (down 346.91% YoY), while the FY2024 annual figure was -$800000.0, down 346.91% from the prior year.
- Tax Provisions for Q4 2024 stood at -$800000.0, down from $4.2 million in the prior quarter.
- The five-year high for Tax Provisions was $4.2 million in Q4 2023, with the low at -$3.9 million in Q3 2023.
- The 4-year median for Tax Provisions is -$200000.0 (2022), against an average of -$155875.0.
- Peak annual rise in Tax Provisions reached 4168.93% in 2023, while the deepest fall reached 1202.02% in 2023.
- Revolution Medicines' Tax Provisions stood at $362000.0 in 2020, then tumbled by 128.45% to -$103000.0 in 2022, then surged by 4168.93% to $4.2 million in 2023, then plunged by 119.09% to -$800000.0 in 2024.
- Business Quant data shows RVMD's Tax Provisions at -$800000.0 in Q4 2024, $4.2 million in Q4 2023, and -$3.9 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 292.00 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 230.90 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 59.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.45 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 267.73 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.31 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.90 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -3.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -800,000.00 |
| Dec 31, 2023 | 4.19 Mn |
| Sep 30, 2023 | -3.87 Mn |
| Dec 31, 2022 | -103,000.00 |
| Sep 30, 2022 | -297,000.00 |
| Dec 31, 2020 | 362,000.00 |
| Jun 30, 2020 | -58,000.00 |
| Mar 31, 2020 | -675,000.00 |